Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients
Open Access
- 5 April 2001
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 84 (7), 915-919
- https://doi.org/10.1054/bjoc.2000.1690
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaNature Medicine, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancerGene Therapy, 1997
- The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.The Journal of Immunology, 1997
- Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.Journal of Clinical Oncology, 1997
- A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.The Journal of Experimental Medicine, 1996
- Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.The Journal of Immunology, 1995
- Low‐dose IL‐2 treatment: Activation of discrete T‐ and NK‐cell sub‐populations in vivoInternational Journal of Cancer, 1995
- Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.The Journal of Immunology, 1995
- A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3European Journal of Immunology, 1994